Could Weight-Loss Drugs Become Alcohol Treatments?

The medicines millions of people take to lose weight may have a second act. Weight-Loss Drugs designed to quiet food cravings are now showing an unexpected effect in clinical trials: they appear to quiet alcohol cravings too. A string of new studies on semaglutide and related medicines suggests the same brain chemistry that drives overeating may also drive heavy drinking, and researchers say the findings could eventually reshape how alcohol use disorder gets treated.

The strongest signal comes from a randomized trial in Denmark. Investigators at Copenhagen University Hospital enrolled one hundred eight adults diagnosed with both alcohol use disorder and obesity, gave half of them a weekly semaglutide injection alongside talk therapy and half an identical placebo, and tracked their drinking for half a year. The group on the active drug cut their heavy drinking days by roughly forty-one percent, outperforming the placebo group by about fourteen percentage points, according to a report on the trial published in The Lancet.

What the trials actually found

The Danish result is notable partly because it did not rely on self-reports alone. Researchers confirmed the reduction in drinking with blood tests for a biomarker of ethanol intake, which guards against the wishful reporting that can skew addiction studies. The calculated number needed to treat was just over four, meaning roughly one in every four treated patients saw a meaningful benefit, a better ratio than the seven or more typically seen with existing alcohol medications. Side effects were limited to mild, temporary nausea, and the semaglutide group also shed excess weight and lowered their blood pressure over the trial.

Weight-Loss Drugs are being tested for addiction in several parallel efforts. At the University of Colorado Anschutz Medical Campus, a team gave an oral form of semaglutide to fifty adults with alcohol use disorder for eight weeks. Participants logged fewer heavy drinking days, drank less on the days they did drink, reported lower day-to-day cravings, and ran into fewer alcohol-related problems than the placebo group, findings reported in the American Journal of Psychiatry. The researchers chose a pill deliberately, betting that people with drinking problems would accept a daily tablet more readily than a weekly injection. Meanwhile, a separate mid-stage trial of an experimental dual-action injection called pemvidutide enrolled one hundred patients and found the drug group logged about four fewer heavy drinking days per week after half a year, a result the drugmaker called highly statistically significant, as reported by BioSpace.

The observational evidence points the same way. A within-individual study of more than one hundred sixty-seven thousand adults with type 2 diabetes in Stockholm County found that periods on a GLP-1 medicine were linked to forty-five percent fewer alcohol-related hospital admissions compared with the same people's unexposed periods, according to LiveWell News. The protective signal lingered for months after prescriptions stopped, then faded, which is exactly the pattern you would expect if the drug itself were doing the work.

Why doctors think appetite drugs touch drinking

The biological story is straightforward. Weight-Loss Drugs mimic a gut hormone that talks to the brain's reward circuitry, dampening the dopamine payoff from food. Alcohol, nicotine, and other drugs hijack the same circuitry, so scientists reasoned early on that a medicine that makes a second helping less appealing might also make a second drink less appealing. "Very few medications are currently approved for alcohol use disorder, and these are vastly underutilized. A new option that is more accessible and more effective could be a gamechanger for closing the treatment gap," said Dr. George Koob, director of the National Institute on Alcohol Abuse and Alcoholism, in comments on the Danish trial.

The gap he describes is enormous. Nearly thirty million adults in the United States live with alcohol use disorder, yet fewer than one in ten receives specialized care and only about two percent are prescribed one of the three medicines regulators have already cleared for the condition: naltrexone, acamprosate, and disulfiram. Those drugs help some patients, but high pill counts and unpleasant side effects make them hard to stick with. A familiar, once-weekly injection or a daily pill with a well-understood safety profile could lower the barrier to starting treatment, especially for people who also want to manage their weight.

The reasons for caution

None of this means the case is closed. A recent meta-analysis pooling three randomized trials with four hundred thirty participants found no statistically significant overall reduction in total alcohol consumption from this drug class, a counterpoint summarized by News-Medical. The review noted that one of the pooled trials was really a smoking-cessation study, which muddies the picture, but its caution is shared widely. In a separate nine-week American trial of low-dose semaglutide in forty-eight people with drinking problems, participants drank less in lab tests and craved alcohol less, yet their total number of drinking days did not budge.

Every expert in this space stresses the same boundary: these medicines are not approved for alcohol use disorder, and no one should chase a prescription for drinking on their own. The trials so far are small and short, they excluded people with severe psychiatric conditions common in addiction, and questions about durability, relapse after stopping, and liver effects are unanswered. The history of addiction medicine is littered with promising early signals that collapsed in bigger trials, which is why a new thirteen-million-dollar study now being organized to test a GLP-1 medicine across alcohol and opioid use disorder matters more than any single headline.

For readers, the practical takeaway is narrower but real. If you or someone you know is struggling with drinking, effective treatments already exist, including counseling and the licensed medicines most people never hear about, and a doctor is the right first conversation. The new research does not change that advice today. What it changes is the horizon: for the first time, addiction medicine has a pipeline of candidates that piggyback on one of the most widely used drug classes on earth. If the larger trials confirm what the early ones suggest, the next decade of alcohol treatment could look very different from the last. Related reading: how a newer weight-loss medicine performed in women, a psychedelic compound that eased inflammation in Parkinson's patients, and why grief support is failing diverse families.